Biotechnology Startups Editing and Proofreading Services

Your data is good. Not conclusive — nobody's is at this stage — but genuinely encouraging, and you have eleven minutes to present it to people who have seen four hundred decks this year and have learned that the encouraging ones are usually built the same way. What separates the companies that raise from the ones that do not is rarely the biology. It is whether the slide showing the result also shows what the result does not establish.

We work on what biotech founders and early companies produce — investor decks and data presentations, scientific and technical summaries for non-specialist investors, pitch narratives and company overviews, grant applications and non-dilutive funding submissions, target product profiles and development plans, scientific advisory board material, licensing and partnering documents, data room content and diligence responses, publication and preprint drafts, and communications about results to investors and boards. Our editors work on the slide the diligence will start from.

The data slide is where biotech fundraising is won or quietly lost, and its failure is presenting an effect without the information needed to size it. An investor with any scientific literacy is asking four questions about every figure — how many, compared with what, how variable, and in what system — and a slide that answers none of them invites them to assume the worst on all four. We work through these so the n is on the slide, in the figure legend if nowhere else, since a striking result in three animals is a different object from the same result in thirty; so the control is named and shown rather than referenced, because "compared with control" conceals whether that means vehicle, standard of care, or nothing at all; so variability is displayed and the error bars are labelled as to what they represent, given that standard error and standard deviation look identical and mean different things; so the model's limitations are stated on the slide in one line rather than in an appendix, as an investor who is told the xenograft model overstates response in this indication is being given a reason to trust the rest; so replication status is named — one experiment, or three independent runs — and so anything that did not work is available rather than absent. Decks built this way survive diligence, which is the only part of fundraising that matters.

Everything you send us stays confidential, including unpublished data, plans and investor material. We are editors rather than scientists, investors or financial advisers, and we offer no view on your data, your programme or your prospects. What we can do is make the slide answer the questions it will be asked.